Flt3-Mutated Acute Leukemia

NEW ORLEANS — In this video perspective, Aaron T. Gerds, MD, MS, discusses a study presented at the ASH Annual Meeting and Exposition comparing daunorubicin regimens for patients with newly diagnosed acute myeloid leukemia. "This study randomized folks between 90 mg/m2 and 60 mg/m2 of daunorubicin and it turned out 60 mg/m2 wasn't any worse," Gerds said, noting, however, that 60 mg/m2 may be associated with more toxicity.

Each year in the U.S., more than 20,000 patients are diagnosed with acute myeloid leukemia — an aggressive and often lethal malignancy — and more than half this number of patients die.

Gilteritinib significantly extended OS and demonstrated higher rates of complete response compared with standard salvage chemotherapy among patients with relapsed or refractory FLT3-mutated acute myeloid leukemia, according to results of the randomized phase 3 ADMIRAL trial published in The New England Journal of Medicine.